Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.
Investigators, led by Hong Kong researcher and Grail collaborator Dennis Lo, described a cancer detection strategy using cleavage patterns in circulating DNA molecules.
Array-based copy number analysis of primary intrahepatic cholangiocarcinomas and matched lymph node metastases revealed a tumor cluster with ties to survival.
The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.
